Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 79-102

  De Petrocellis, Luciano ^a   Ligresti, Alessia ^b   Schiano Moriello, Aniello ^a   Iappelli, Mariagrazia ^a   Verde, Roberta ^b   Stott, Colin G ^c   Cristino, Luigia ^a   Orlando, Pierangelo ^d   Di Marzo, Vincenzo ^b  

^a CNR   (Italy)

^b CNR   (Italy)

^c Porton Down Science Park   (United Kingdom)

^d INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

Author keywords

androgen; apoptosis; cannabinoid; prostate; ROS; TRP channel

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CALCIUM ION; CANNABICHROMENE; CANNABIDIOL; CANNABIDIOLIC ACID; CANNABIDIVARIN; CANNABIGEROL; CANNABIGEROLIC ACID; CANNABIGEVARIN; CANNABINOID DERIVATIVE; CANNABIS; CASPASE 3; CASPASE 7; DELTA9 TETRAHYDROCANNABIVARIN; DELTA9 TETRAHYDROCANNABIVARINIC ACID; DOCETAXEL; DRONABINOL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; TETRAHYDROCANNABINOLIC ACID; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; APOPTOSIS; CANNABIDIOL; CANNABINOIDS; CASPASE 3; CELL CYCLE; CELL SURVIVAL; DOWN-REGULATION; DRONABINOL; DRUG INTERACTIONS; HUMANS; MALE; MICE; MICE, NUDE; NITRILES; PROSTATE; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; TAXOIDS; TOSYL COMPOUNDS; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRPM CATION CHANNELS; TUMOR CELLS, CULTURED;

EID: 84872555149     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02027.x     Document Type: Article

References (88)

1. Aghaei M, Karami-Tehrani F, Panjehpour M, Salami S, Fallahian F, (2012). Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3. Prostate 72: 361-375.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164: S1-324.
3. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al,. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90: 925-933.
4. Bab I, (2011). Themed issue on cannabinoids in biology and medicine. Br J Pharmacol 163: 1327-1328.
5. Bahnson R, (2007). Androgen deprivation therapy for prostate cancer. J Urol 178: 1148.
6. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, et al,. (1994). Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A 91: 5330-5334.
7. Bidaux G, Roudbaraki M, Merle C, Crepin A, Delcourt P, Slomianny C, et al,. (2005). Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr Relat Cancer 12: 367-382.
8. Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, et al,. (2007). Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest 117: 1647-1657.
9. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, et al,. (2001). Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745-2747.
10. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al,. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
11. Blázquez C, Casanova ML, Planas A, Gomez Del Pulgar T, Villanueva C, Fernandez-Acenero MJ, et al,. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531.
12. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al,. (2003). Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225.
13. Caffarel MM, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G, et al,. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9: 196-206.
14. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, et al,. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 43-50.
15. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, et al,. (2010). Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17: 1511-1523.
16. Cheung CP, Yu S, Wong KB, Chan LW, Lai FM, Wang X, et al,. (2005). Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 90: 1830-1844.
17. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, et al,. (2009). Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15: 4815-4822.
18. Contassot E, Tenan M, Schnuriger V, Pelte MF, Dietrich PY, (2004). Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93: 182-188.
19. Cox ME, Deeble PD, Lakhani S, Parsons SJ, (1999). Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59: 3821-3830.
20. Czifra G, Varga A, Nyeste K, Marincsak R, Toth BI, Kovacs I, et al,. (2009). Increased expression of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol 135: 507-514.
21. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al,. (1998). The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95: 8375-8380.
22. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al,. (2008). Plant derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325: 1007-1015.
23. De Petrocellis L, Ligresti A, Schiano Moriello A, Allarà M, Bisogno T, Petrosino S, et al,. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
24. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al,. (2009). In vivo effects of a GPR30 antagonist. Nat Chem Biol 5: 421-427.
25. Dillard PR, Lin MF, Khan SA, (2008). Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295: 115-120.
26. Drysdale AJ, Ryan D, Pertwee RG, Platt B, (2006). Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 50: 621-631.
27. 9-tetrahydrocannabinol and diazepam to human serum albumin. IUBMB Life 63: 446-451.
28. Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA, (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat CNS Drug Discov 4: 112-136.
29. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al,. (2007). miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724.
30. Gertsch J, Pertwee RG, Di Marzo V, (2010). Phytocannabinoids beyond the Cannabis plant-do they exist? Br J Pharmacol 160: 523-529.
31. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, et al,. (2009). The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106: 11131-11136.
32. Guindon J, Hohmann AG, (2011). The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463.
33. Gustafsson SB, Lindgren T, Jonsson M, Jacobsson SO, (2009). Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 63: 691-701.
34. 2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. J Physiol 517: 95-107.
35. Hartel A, Didier A, Ulbrich SE, Wierer M, Meyer HH, (2004). Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes. J Steroid Biochem Mol Biol 92: 187-197.
36. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, et al,. (2003). Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63: 4196-4203.
37. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al,. (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
38. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
39. Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ, (2000). Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807-1813.
40. Jacobsson SO, Wallin T, Fowler CJ, (2001). Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299: 951-959.
41. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
42. Kruse JP, Gu W, (2009). Modes of p53 regulation. Cell 137: 609-622.
43. Lee SY, Oh SM, Lee SK, Chung KH, (2005). Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res 28: 1365-1375.
44. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, et al,. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687.
45. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al,. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
46. Lim MP, Devi LA, Rozenfeld R, (2011). Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis 2: e170.
47. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrò A, (2000). Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938-31945.
48. Malagarie-Cazenave S, Olea-Herrero N, Vara D, Diaz-Laviada I, (2009). Capsaicin, a component of red peppers, induces expression of androgen receptor via PI3K and MAPK pathways in prostate LNCaP cells. FEBS Lett 583: 141-147.
49. Malagarie-Cazenave S, Olea-Herrero N, Vara D, Morell C, Diaz-Laviada I, (2011). The vanilloid capsaicin induces IL-6 secretion in prostate PC-3 cancer cells. Cytokine 54: 330-337.
50. Marchiani S, Tamburrino L, Nesi G, Paglierani M, Gelmini S, Orlando C, et al,. (2010). Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Int J Androl 33: 784-793.
51. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D, (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-845.
52. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, et al,. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129: 37-47.
53. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
54. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, et al,. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118-126.
55. Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP, (2003). Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor downregulation and ceramide production. Prostate 56: 1-12.
56. Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, et al,. (2010). Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res 70: 1225-1235.
57. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA, (1975). Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55: 597-602.
58. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, et al,. (2011). Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 18: 846-856.
59. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Diaz-Laviada I, (2009). Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950.
60. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V, (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65: 1473-1481.
61. Ortar G, De Petrocellis L, Morera L, Moriello AS, Orlando P, Morera E, et al,. (2010). (-)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. Bioorg Med Chem Lett 20: 2729-2732.
62. Papa VM, Shen ML, Ou DW, (1990). The effects of pH and temperature on the in vitro bindings of delta-9-tetrahydrocannabinol and other cannabinoids to bovine serum albumin. J Pharm Biomed Anal 8: 353-356.
63. Pfaffl MW, (2010). The ongoing evolution of qPCR. Methods 50: 215-216.
64. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M, (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773.
65. 9- Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27: 339-334.
66. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM, (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28: 6231-6238.
67. Ramer R, Merkord J, Rohde H, Hinz B, (2010). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 79: 955-966.
68. Ren J, Wu JH, (2012). 17β-Estradiol rapidly activates calcium release from intracellular stores via the GPR30 pathway and MAPK phosphorylation in osteocyte-like MLO-Y4 cells. Calcif Tissue Int 90: 411-419.
69. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER, (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science 307: 1625-1630.
70. Robson P, (2005). Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 168: 719-756.
71. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, et al,. (2005). Androgen regulates apoptosis induced by TNFR family ligands via multiple signalling pathways in LNCaP. Oncogene 24: 6773-6784.
72. Ruh MF, Taylor JA, Howlett AC, Welshons WV, (1997). Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53: 35-41.
73. 9- tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458: 400-404.
74. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
75. Sanchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, et al,. (2001). Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61: 5784-5789.
76. Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, et al,. (2005). Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol 515: 20-27.
77. Sanchez AM, Sanchez MG, Malagarie-Cazenave S, Olea N, Diaz-Laviada I, (2006). Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 11: 89-99.
78. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H, (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641.
79. Schiewer MJ, Augello MA, Knudsen KE, (2012). The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol 352: 34-45.
80. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A, (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10: 1161-1172.
81. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, et al,. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10: 90-103.
82. Tsavaler L, Shapero MH, Morkowski S, Laus R, (2001). Trp-p8, a novel prostate-specific gene, is upregulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61: 3760-3769.
83. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D, (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-1036.
84. Valero M, Morenilla-Palao C, Belmonte C, Viana F, (2011). Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch 461: 99-114.
85. 9-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268: 531-535.
86. Yu J, Zhang L, (2008). PUMA, a potent killer with or without p53. Oncogene 27: S71-S83.
87. 2+ channel required for the survival of prostate cancer cells. Cancer Res 64: 8365-8373.
88. Ziglioli F, Frattini A, Maestroni U, Dinale F, Ciufifeda M, Cortellini P, (2009). Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV-1 dependent and a TRPV-1-independent mechanism. Acta Biomed 80: 13-20.